Calamansi Powder Capsule Supplementation
Conditions
Brief summary
Fifty-four healthy sedentary male and female participants aged 18-30 years will be recruited for this study. Participants will be randomly assigned to one of two groups: a control group receiving placebo MMC capsules (n = 27) or a calamansi capsule supplementation group (n = 27). All participants will undergo health screening procedures, including medical history assessment, mental health questionnaire evaluation, and measurements of vital signs, height, body weight, and body composition. Venous blood samples will subsequently be collected to determine blood glucose, insulin, creatinine, alanine aminotransferase (ALT), and malondialdehyde (MDA) levels. These assessments will be performed at three time points: 1) before capsule supplementation (baseline), 2) following a single dose of capsule supplementation, and 3) after 12 weeks of supplementation.
Interventions
OTHERMMC powder capsule
Each capsule contains MMC powder for 500 mg
DIETARY_SUPPLEMENTCalamansi powder capsule
Each capsule contains calamansi powder for 500 mg
Sponsors
Burapha University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Intervention model description
Participants will be randomly divided into 2 groups consisting of placebo group (n = 27) or a treatment group (n = 27).
Eligibility
Sex/Gender
ALL
Age
18 Years to 30 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy individuals who have not been diagnosed with diabetes or prediabetes, with a fasting blood glucose level (after 8 hours of fasting) of less than 100 mg/dL. * Aged between 18-30 years, both male and female * Body Mass Index (BMI) between 18.5 and 22.9 kg/m² * No diseases affecting blood sugar levels, such as liver or pancreatic diseases
Exclusion criteria
* Pregnant or breastfeeding women * Regular smokers * Regular alcohol consumers * Individuals with a history of allergies to citrus fruits or citrus-derived ingredients * Individuals taking medications that affect glucose metabolism and fat distribution in the body, including steroids, protease inhibitors, and psychiatric medications. These refer to drugs that act on the central nervous system and may affect blood sugar levels or energy metabolism, such as antidepressants, antipsychotics, and mood stabilizers.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Concentrations of blood malondialdehyde | At 0 minute before consumption, at 120 minute after consumption, and at days 91 after consumption | Concentrations of blood malondialdehyde were measured before and after MMC capsules or calamansi capsule consumption at 500 mg in uM (micromolar) unit |
| Concentrations of blood glucose | At 0 minute before consumption, at 30, 60, 90, 120 minutes after consumption, and at days 91 after consumption | Concentrations of blood glucose were measured before and after MMC capsules or calamansi capsule consumption at 500 mg in mg/dL unit |
| Concentrations of blood insulin | At 0 minute before consumption, at 120 minute after consumption, and at days 91 after consumption | Concentrations of blood insulin were measured before and after MMC capsules or calamansi capsule consumption at 500 mg in uU/mL (microunit/milliliter) unit |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Levels of heart rate variability | At 0-10 minutes before consumption, at 110-120 minutes after consumption, and at days 91 after consumption for 10 minutes | Heart rate variability were measured before and after MMC capsules or calamansi capsule consumption at 500 mg in ms (milliseconds) and ms2 (millisecond squared) unit |
Countries
Thailand
Contacts
CONTACTPiyapong Prasertsri, Ph.D.
CONTACTKulwara Poolpol, Ph.D.
PRINCIPAL_INVESTIGATORPiyapong Prasertsri, Ph.D.
Faculty of Allied Health Sciences, Burapha University
Outcome results
None listed